Cargando…

Quantification of individual remyelination during short-term disease course by synthetic magnetic resonance imaging

MRI is an important diagnostic tool for evaluation of myelin content in multiple sclerosis and other CNS diseases, being especially relevant for studies investigating remyelinating pharmacotherapies. In this study, we evaluated a new synthetic MRI–based myelin estimation in methylenetetrahydrofolate...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Ruth, Matusche, Britta, Ladopoulos, Theodoros, Ayzenberg, Ilya, Biesalski, Anne Sophie, Gold, Ralf, Bellenberg, Barbara, Lukas, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351729/
https://www.ncbi.nlm.nih.gov/pubmed/35938071
http://dx.doi.org/10.1093/braincomms/fcac172
_version_ 1784762495749062656
author Schneider, Ruth
Matusche, Britta
Ladopoulos, Theodoros
Ayzenberg, Ilya
Biesalski, Anne Sophie
Gold, Ralf
Bellenberg, Barbara
Lukas, Carsten
author_facet Schneider, Ruth
Matusche, Britta
Ladopoulos, Theodoros
Ayzenberg, Ilya
Biesalski, Anne Sophie
Gold, Ralf
Bellenberg, Barbara
Lukas, Carsten
author_sort Schneider, Ruth
collection PubMed
description MRI is an important diagnostic tool for evaluation of myelin content in multiple sclerosis and other CNS diseases, being especially relevant for studies investigating remyelinating pharmacotherapies. In this study, we evaluated a new synthetic MRI–based myelin estimation in methylenetetrahydrofolate reductase deficiency as a treatable primary demyelinating disorder and compared this method with established diffusion tensor imaging in both methylenetetrahydrofolate reductase deficiency patients and healthy controls. This is the first synthetic MRI–based in vivo evaluation of treatment-associated remyelination. 1.5 T synthetic MRI and 3 T diffusion MRI were obtained from three methylenetetrahydrofolate reductase deficiency patients at baseline and 6 months after therapy initiation, as well as from age-matched healthy controls (diffusion tensor imaging: n = 14, synthetic MRI: n = 9). Global and regional synthetic MRI parameters (myelin volume fraction, proton density, and relaxation rates) were compared with diffusion metrics (fractional anisotropy, mean/radial/axial diffusivity) and related to healthy controls by calculating z-scores and z-deviation maps. Whole-brain myelin (% of intracranial volume) of the index patient was reduced to 6 versus 10% in healthy controls, which recovered to a nonetheless subnormal level of 6.6% following initiation of high-dosage betaine. Radial diffusivity was higher at baseline compared with healthy controls (1.34 versus 0.79 × 10(−3) mm(2)/s), recovering at follow-up (1.19 × 10(−3) mm(2)/s). The index patient’s lesion volume diminished by 58% under treatment. Regional analysis within lesion area and atlas-based regions revealed lower mean myelin volume fraction (12.7(Baseline)/14.71(Follow-up)%) and relaxation rates, higher proton density, as well as lower fractional anisotropy and higher radial diffusivity (1.08 × 10(−3)(Baseline)/0.94 × 10(−3)(Follow-up)) compared with healthy controls. The highest z-scores were observed for myelin volume fraction in the posterior thalamic radiation, with greater deviation from controls at baseline and reduced deviation at follow-up. Z-deviations of diffusion metrics were less pronounced for radial and mean diffusivity than for myelin volume fraction. Z-maps for myelin volume fraction of the index patient demonstrated high deviation within and beyond lesion areas, among others in the precentral and postcentral gyrus, as well as in the cerebellum, and partial remission of these alterations at follow-up, while radial diffusivity demonstrated more widespread deviations in supra- and infratentorial regions. Concordant changes of myelin volume fraction and radial diffusivity after treatment initiation, accompanied by dramatic clinical and paraclinical improvement, indicate the consistency of the methods, while myelin volume fraction seems to characterize remyelinated regions more specifically. Synthetic MRI–based myelin volume fraction provides myelin estimation consistent with changes of diffusion metrics to monitor short-term myelin changes on individual patient level.
format Online
Article
Text
id pubmed-9351729
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-93517292022-08-05 Quantification of individual remyelination during short-term disease course by synthetic magnetic resonance imaging Schneider, Ruth Matusche, Britta Ladopoulos, Theodoros Ayzenberg, Ilya Biesalski, Anne Sophie Gold, Ralf Bellenberg, Barbara Lukas, Carsten Brain Commun Original Article MRI is an important diagnostic tool for evaluation of myelin content in multiple sclerosis and other CNS diseases, being especially relevant for studies investigating remyelinating pharmacotherapies. In this study, we evaluated a new synthetic MRI–based myelin estimation in methylenetetrahydrofolate reductase deficiency as a treatable primary demyelinating disorder and compared this method with established diffusion tensor imaging in both methylenetetrahydrofolate reductase deficiency patients and healthy controls. This is the first synthetic MRI–based in vivo evaluation of treatment-associated remyelination. 1.5 T synthetic MRI and 3 T diffusion MRI were obtained from three methylenetetrahydrofolate reductase deficiency patients at baseline and 6 months after therapy initiation, as well as from age-matched healthy controls (diffusion tensor imaging: n = 14, synthetic MRI: n = 9). Global and regional synthetic MRI parameters (myelin volume fraction, proton density, and relaxation rates) were compared with diffusion metrics (fractional anisotropy, mean/radial/axial diffusivity) and related to healthy controls by calculating z-scores and z-deviation maps. Whole-brain myelin (% of intracranial volume) of the index patient was reduced to 6 versus 10% in healthy controls, which recovered to a nonetheless subnormal level of 6.6% following initiation of high-dosage betaine. Radial diffusivity was higher at baseline compared with healthy controls (1.34 versus 0.79 × 10(−3) mm(2)/s), recovering at follow-up (1.19 × 10(−3) mm(2)/s). The index patient’s lesion volume diminished by 58% under treatment. Regional analysis within lesion area and atlas-based regions revealed lower mean myelin volume fraction (12.7(Baseline)/14.71(Follow-up)%) and relaxation rates, higher proton density, as well as lower fractional anisotropy and higher radial diffusivity (1.08 × 10(−3)(Baseline)/0.94 × 10(−3)(Follow-up)) compared with healthy controls. The highest z-scores were observed for myelin volume fraction in the posterior thalamic radiation, with greater deviation from controls at baseline and reduced deviation at follow-up. Z-deviations of diffusion metrics were less pronounced for radial and mean diffusivity than for myelin volume fraction. Z-maps for myelin volume fraction of the index patient demonstrated high deviation within and beyond lesion areas, among others in the precentral and postcentral gyrus, as well as in the cerebellum, and partial remission of these alterations at follow-up, while radial diffusivity demonstrated more widespread deviations in supra- and infratentorial regions. Concordant changes of myelin volume fraction and radial diffusivity after treatment initiation, accompanied by dramatic clinical and paraclinical improvement, indicate the consistency of the methods, while myelin volume fraction seems to characterize remyelinated regions more specifically. Synthetic MRI–based myelin volume fraction provides myelin estimation consistent with changes of diffusion metrics to monitor short-term myelin changes on individual patient level. Oxford University Press 2022-06-28 /pmc/articles/PMC9351729/ /pubmed/35938071 http://dx.doi.org/10.1093/braincomms/fcac172 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Schneider, Ruth
Matusche, Britta
Ladopoulos, Theodoros
Ayzenberg, Ilya
Biesalski, Anne Sophie
Gold, Ralf
Bellenberg, Barbara
Lukas, Carsten
Quantification of individual remyelination during short-term disease course by synthetic magnetic resonance imaging
title Quantification of individual remyelination during short-term disease course by synthetic magnetic resonance imaging
title_full Quantification of individual remyelination during short-term disease course by synthetic magnetic resonance imaging
title_fullStr Quantification of individual remyelination during short-term disease course by synthetic magnetic resonance imaging
title_full_unstemmed Quantification of individual remyelination during short-term disease course by synthetic magnetic resonance imaging
title_short Quantification of individual remyelination during short-term disease course by synthetic magnetic resonance imaging
title_sort quantification of individual remyelination during short-term disease course by synthetic magnetic resonance imaging
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351729/
https://www.ncbi.nlm.nih.gov/pubmed/35938071
http://dx.doi.org/10.1093/braincomms/fcac172
work_keys_str_mv AT schneiderruth quantificationofindividualremyelinationduringshorttermdiseasecoursebysyntheticmagneticresonanceimaging
AT matuschebritta quantificationofindividualremyelinationduringshorttermdiseasecoursebysyntheticmagneticresonanceimaging
AT ladopoulostheodoros quantificationofindividualremyelinationduringshorttermdiseasecoursebysyntheticmagneticresonanceimaging
AT ayzenbergilya quantificationofindividualremyelinationduringshorttermdiseasecoursebysyntheticmagneticresonanceimaging
AT biesalskiannesophie quantificationofindividualremyelinationduringshorttermdiseasecoursebysyntheticmagneticresonanceimaging
AT goldralf quantificationofindividualremyelinationduringshorttermdiseasecoursebysyntheticmagneticresonanceimaging
AT bellenbergbarbara quantificationofindividualremyelinationduringshorttermdiseasecoursebysyntheticmagneticresonanceimaging
AT lukascarsten quantificationofindividualremyelinationduringshorttermdiseasecoursebysyntheticmagneticresonanceimaging